留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

"Polypill"的发展及前景

向丽 姜鹏 胡耀华 王淑萍 张卫东 柳润辉

向丽, 姜鹏, 胡耀华, 王淑萍, 张卫东, 柳润辉. 'Polypill'的发展及前景[J]. 药学实践与服务, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
引用本文: 向丽, 姜鹏, 胡耀华, 王淑萍, 张卫东, 柳润辉. "Polypill"的发展及前景[J]. 药学实践与服务, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
XIANG Li, JIANG Peng, HU Yao-hua, WANG Shu-ping, ZHANG Wei-dong, LIU Run-hui. Progress and prospect on Polypill[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
Citation: XIANG Li, JIANG Peng, HU Yao-hua, WANG Shu-ping, ZHANG Wei-dong, LIU Run-hui. Progress and prospect on Polypill[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001

"Polypill"的发展及前景

doi: 10.3969/j.issn.1006-0111.2012.03.001

Progress and prospect on Polypill

  • 摘要: 慢性疾病的发病率越来越高,尤其是心脑血管疾病,已成为人类死亡的首要原因。由于心脑血管疾病是由多种危险因素诱发,仅仅使用单一的药物远远不能达到预防或治疗的目的。基于此出现了多效药物"Polypill"的概念,具有使用方便、成本低、提高了患者对药物的依从性等特点。本文就"Polypill"的研究发展及应用前景进行综述。
  • [1] Available from:http://www.who.int/cardiovascular diseases/en/.
    [2] Yusuf S,Reddy S,Ounpuu S,et al.Global burden of cardiovascular disease:part Ⅱ:variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies[J].Circulation,2001,104(23):2855.
    [3] Bonow RO,Smaha LA,Smith SC,et al.The international burden of cardiovascular disease: responding to the emerging global epidemic[J].Circulation 2002,106:1602.
    [4] Yusuf S. Two decades of progress in preventing vascular disease[J].Lancet,2002360(9326):2.
    [5] Wald NJ,Law MR.A strategy to reduce cardiovascular disease by more than 80%[J]. BMJ,2003,326(7404):1419.
    [6] Jennifer GR.A"Poly-Portfolio" for Secondary Prevention: A strategy to reduce subsequent events by up to 97% over five years[J]. Am J Cardiol,2005,95(3):373.
    [7] Thomas AG, Lionel HO, Milton CW.Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis[J].Lancet.2006,19:679.
    [8] Vijay K, Ravi PS, Saranjit S.LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases Part 1. Separation of active components and classification of their interaction/degradation products[J].J Pharmaceut Blomed, 2008,47:508.
    [9] Vijay K, Bhagwat P, Saranjit S.Pharmaceutical issues in the development of a polypill for the treatment of cardiovascular diseases[J].D Drug Dev. Ind. Pharm,2008,5(1): 63.
    [10] Yusuf S,Pais PEffects of a polypill(Polycap)on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase 11, double-blind, randomised trial[J].Lancet, 2009,373(9672):1341.
    [11] Davey SG, Ebrahim S. Folate supplementation and cardiovascular disease[J].Lancet, 2005,366:1679.
    [12] Rastegarpanah M, Malekzadeh F, Thomas GN, et al.A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"?[J].Archivs of Iranian Medicine, 2008,11(3):306.
    [13] Salerno CM, Demopoulos L, Mukherjee R, et al.Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension[J].J Clin Hypertens,2004,6:614.
    [14] Leventhal MJ, Riegel B, Carlson B, el al.Negotiating compliance in heart failure: Remaining issues and questions[J].Eur J Cardiovase Nurs,2005,4:298.
    [15] Newby LK, La PNM, Chen AY, et al.Long term adherence to evidencebased secondary prevention therapies in coronary artery disease[J].Circulation,2006,113(2):203.
    [16] 曹东来,扬向军.PCI术后冠心病病人他汀类药依从性分析[J].中国血液流变学杂志,2004,14(1):126.
    [17] Fuster V, Voute J. MDGs: chronic diseases are not on the agenda[J].Lancet,2005,366:1512.
    [18] Murray CJL, Lauer JA, Hutubessy RC, et al.Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk[J].Lancet,2003;361:717.
    [19] Yusuf S, Hawken S, Ounpuu S, et al.Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study[J].Lancet, 2004,364:937.
    [20] Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials[J]. BMJ,2003,326:1427.
    [21] Lonn E, Yusuf S.Polypill: the evidence and the promise[J]. CURR OPIN LIPIDOL.2009,20(6):453.
    [22] Frishman WH, Ztmkerman AL.Amlodi pjne/atovrastatin: tile first cross risk factor polypill for tile prevention and treatment of caldiovaseular disease[J].Expert Prey Cardiovasc Ther,2004,2675:681.
    [23] Zwolska Z, Niemirowska H, Augustynowicz E, et al.Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules[J].Int J Tuberc Lung Dis,2(10):824.
    [24] Kulkanya C, Nottasorn P, Tim RC, et al.Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine[J]. AIDS,2005,19:1495.
    [25] Freedberg KA, Losina E, Weinstein MC, et al.The cost effectiveness of combination antiretroviral therapy for HIV disease[J].N Engl J Med,2001,334:824.
    [26] Bakshi R, Hermeling I, Gathmann I, et al.An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug[J]. T Roy Soc Trop Med H,2000,94:419.
    [27] Valentin F.Prime time for a polypill after myocardial infraction[J]. Nat Clin Pract Card,2009,6:83.
    [28] http://www.emea.europa.eu/htms/human/epar/a.htm.
    [29] Lonn E, Yusuf S.Polypill: the evidence and the promise[J]. Curr Opin Lipidol 2009,20(6):453.
    [30] Pearson TA, Blair SN, Daniels SR, et al.AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases[J].Circulation,2002,106:388.
    [31] Jha P, Peto R, Zatonsky W, et al.Social inequalities in male mortality and in male mortality from smoking: indirect estimation natio from nal death rates in England and Wales, Poland, and North america[J].Lancet,2006,368:367.
    [32] NCEP Expert Panel.Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in Adults (Adult Treatment Panel III)[J].JAMA,2001,285:2486.
    [33] Williams PT.Physical fitness and activity as separate heart disease risk factors: a meta-analysis[J].Med Sci Sports Exerc,2001,33:754.
    [34] Blair SN, Kampert JB, Kohl HW III, et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women[J].JAMA,1996,276:205.
  • [1] 孙雨菡, 许子艺, 廖峻, 张翮, 卢光照, 樊莉, 鲁莹.  高效液相色谱法同时测定盐酸阿霉素与氯尼达明的含量 . 药学实践与服务, 2023, 41(): 1-4. doi: 10.12206/j.issn.2097-2024.202306043
    [2] 段虎, 周艳卿, 钱瑜琳, 赵亮.  某二级医院稳定期慢性阻塞性肺疾病患者吸入治疗依从性及其影响因素 . 药学实践与服务, 2023, 41(): 1-5. doi: 10.12206/j.issn.2097-2024.202204094
    [3] 唐人杰, 李志勇, 王瑞娜, 刘佳存, 王智, 刘海燕, 李红磊, 王旭, 张大志, 阎澜.  基于Morisky量表调查某院校学员浅部真菌病用药依从性 . 药学实践与服务, 2022, 40(4): 335-338. doi: 10.12206/j.issn.1006-0111.202107016
    [4] 王辉, 李歆, 陈敬.  试点城市带量采购政策对某三级综合医院门诊心血管类原研药和仿制药利用状况的影响 . 药学实践与服务, 2020, 38(4): 373-378. doi: 10.12206/j.issn.1006-0111.202001054
    [5] 叶腾飞, 程涛, 宋平, 卞晓岚.  药学干预对社区高血压患者用药依从性的影响 . 药学实践与服务, 2018, 36(6): 573-576. doi: 10.3969/j.issn.1006-0111.2018.06.022
    [6] 蔡建, 李明明, 张平, 费春华, 钱昌, 徐峰.  门诊抑郁患者的药物品牌偏好及对用药依从性和疗效的影响 . 药学实践与服务, 2017, 35(2): 154-157,164,181. doi: 10.3969/j.issn.1006-0111.2017.02.014
    [7] 邵腾飞, 葛卫红.  临床药师干预对脑梗死患者用药依从性的影响 . 药学实践与服务, 2017, 35(2): 178-181. doi: 10.3969/j.issn.1006-0111.2017.02.021
    [8] 马宗强, 安洪亮.  门诊口服抗高血压药物的调查分析 . 药学实践与服务, 2016, 34(2): 188-190,192. doi: 10.3969/j.issn.1006-0111.2016.02.024
    [9] 赵佳丽, 陈秋红, 李红娜, 曾莉莉, 叶永贤, 费燕.  神经病理性疼痛的药物治疗进展 . 药学实践与服务, 2016, 34(4): 309-312. doi: 10.3969/j.issn.1006-0111.2016.04.006
    [10] 赵柳娅, 曹颖瑛, 姜远英.  两性霉素B联合用药的研究进展 . 药学实践与服务, 2014, 32(1): 1-4,8. doi: 10.3969/j.issn.1006-0111.2014.01.001
    [11] 成彦琼, 张浩, 王威, 顾小飞, 刘爱军.  叶酸在心脑血管疾病防治中的机遇与挑战 . 药学实践与服务, 2013, 31(5): 330-333,350. doi: 10.3969/j.issn.1006-0111.2013.05.003
    [12] 韦龙静.  抑郁症治疗依从性研究概述 . 药学实践与服务, 2012, 30(6): 415-417,474. doi: 10.3969/j.issn.1006-0111.2012.06.005
    [13] 陈开宇, 江丽萍, 陈盛新.  慢性阻塞性肺疾病的药物治疗进展 . 药学实践与服务, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003
    [14] 梁光荣, 唐巧金, 倪渊.  医院药师在提高患者用药依从性中的作用 . 药学实践与服务, 2009, 27(2): 150-151,153,156.
    [15] 赵民生, 曹秀虹.  利尿剂在治疗心血管疾病时的不良反应及处理 . 药学实践与服务, 2006, (6): 353-354.
    [16] 赵国玺, 傅鹰.  随机对照双盲试验中病例剔除情况的分析 . 药学实践与服务, 2005, (2): 93-95.
    [17] 唐斌, 何佩珍, 徐帆, 尚北城.  黄连素的联合用药 . 药学实践与服务, 2005, (5): 278-281.
    [18] 路绪文, 刘晋华, 陈静然.  黄芪与心血管疾病 . 药学实践与服务, 2002, (1): 3-6.
    [19] 张生大.  双嘧达莫与其它药物合用的新用途 . 药学实践与服务, 2001, (1): 13-13.
    [20] 崔清江, 史俊义.  儿科合理用药与患儿家长的依从性 . 药学实践与服务, 1996, (6): 365-366.
  • 加载中
计量
  • 文章访问数:  3676
  • HTML全文浏览量:  237
  • PDF下载量:  921
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-04-26
  • 修回日期:  2011-12-18

"Polypill"的发展及前景

doi: 10.3969/j.issn.1006-0111.2012.03.001

摘要: 慢性疾病的发病率越来越高,尤其是心脑血管疾病,已成为人类死亡的首要原因。由于心脑血管疾病是由多种危险因素诱发,仅仅使用单一的药物远远不能达到预防或治疗的目的。基于此出现了多效药物"Polypill"的概念,具有使用方便、成本低、提高了患者对药物的依从性等特点。本文就"Polypill"的研究发展及应用前景进行综述。

English Abstract

向丽, 姜鹏, 胡耀华, 王淑萍, 张卫东, 柳润辉. 'Polypill'的发展及前景[J]. 药学实践与服务, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
引用本文: 向丽, 姜鹏, 胡耀华, 王淑萍, 张卫东, 柳润辉. "Polypill"的发展及前景[J]. 药学实践与服务, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
XIANG Li, JIANG Peng, HU Yao-hua, WANG Shu-ping, ZHANG Wei-dong, LIU Run-hui. Progress and prospect on Polypill[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
Citation: XIANG Li, JIANG Peng, HU Yao-hua, WANG Shu-ping, ZHANG Wei-dong, LIU Run-hui. Progress and prospect on Polypill[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(3): 161-164,228. doi: 10.3969/j.issn.1006-0111.2012.03.001
参考文献 (34)

目录

    /

    返回文章
    返回